Corbus Pharmaceuticals announes data for CRB-701 from Western Dose study

Corbus Pharmaceuticals (CRBP) announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom of CRB-701 will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, to be held in San Francisco, CA February 13-15, 2025.